Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion Criteria to be checked at the screening visit (SC):~* Aged 0 to 7 days on the day of screening~* Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg~* Informed consent form signed by the parent(s) or other legally acceptable representative~* Subjects and parent/guardian able to attend all scheduled visits and comply with all trial procedures~* Inclusion Criteria to be checked at the randomization visit (V01):~* Aged 42 to 50 days on the day of inclusion~* Subjects and parent/guardian able to attend all scheduled visits and comply with all trial procedures~Exclusion Criteria:~* Exclusion Criteria to be checked at the screening visit (SC):~* Planned participation in another clinical trial during the present trial period~* Illness that could interfere with trial conduct or completion, in the opinion of the investigator~* Receipt of blood or blood-derived products since birth that might interfere with the assessment of immune response~* History of seizures~* Known personal or maternal Human Immunodeficiency Virus (HIV), Hepatitis B antigen or Hepatitis C seropositivity~* Thrombocytopenia or bleeding disorder contraindicating IM injection~* Exclusion Criteria to be checked at the randomization visit (V01):~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination~* Planned participation in another clinical trial during the present trial period~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy~* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances~* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the investigator~* Receipt of blood or blood-derived products since birth that might interfere with the assessment of immune response~* Receipt or planned receipt of any vaccine in the 4 weeks preceding or following any trial vaccination (except BCG, DTP-Hib or Hepatitis B vaccines, which can not be given within 10 days before or after any study vaccination)~* History of seizures~* Known personal or maternal Human Immunodeficiency Virus (HIV), Hepatitis B antigen or Hepatitis C seropositivity~* History of poliomyelitis infection (confirmed either clinically, serologically or microbiologically)~* Previous vaccination against the poliomyelitis disease with either the trial vaccine or another vaccine~* Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular (IM) injection~* Febrile illness (temperature ≥38°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 50 Days
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): None
- Group B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).